Q-omics provides the consensus-scored LRRK2-DT profile across patient tissues and cancer cell-line models. LRRK2-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRK2-DT is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, LRRK2-DT RNA expression shows 17,487 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where LRRK2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRK2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRK2-DT survival associations across molecular data types. LRRK2-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRK2-DT RNA expression–survival associations across cancer types. High LRRK2-DT expression shows unfavorable associations in BLCA, but favorable associations in KIRC, KIRP, SKCM, THCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRK2-DT RNA expression.
This table summarizes LRRK2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LRRK2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRK2-DT shows lower tumor expression in LUAD, KICH, COAD, LUSC and BLCA and higher tumor expression in THCA. The LUAD box plot shows higher LRRK2-DT RNA expression in normal versus tumor tissue (log2 FC = −3.724, t-test p < 0.001).
This table shows molecular features associated with LRRK2-DT in patient tissues and cancer cell lines. In patient samples, LRRK2-DT shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
